Lomtegovimab Biosimilar - Research Grade

Human

Severe acute respiratory syndrome coronavirus 2

5mg/ml

IgG1 - kappa

CHO Cells

https://www.imgt.org/mAb-DB/

ICH3002

Blue ice

Neutralizing antibodies against the SARS-CoV-2 surface antigen remain essential tools for infectious-disease and antiviral countermeasure research. Built as an unconjugated, non-therapeutic analog of lomtegovimab, this human IgG1 (kappa) recombinant antibody binds the SARS-CoV-2 antigen and is offered for research use only (RUO). The preparation carries a low endotoxin burden suitable for in vivo work and is generated at scalable milligram-to-gram volumes, supporting laboratories with sustained or high-throughput demand. It functions as a dependable reference and active reagent in viral neutralization assays, in vitro binding screens, and preclinical in vivo challenge models exploring protection and immune mechanisms.

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks